Aratana Therapeutics to be Acquired by Elanco Animal Health

The Company announced it has signed an agreement to be acquired by Elanco Animal Health (NYSE: ELAN), its global collaboration partner on GALLIPRANT® (grapiprant tablets). In conjunction with the transaction, Elanco also announced the formation of a commercial team dedicated to the veterinary specialty business. If the proposed agreement is consummated, the Aratana field force would transition into this commercial team.